Ginkgo Bioworks Holdings (DNA) EBT Growth (3y) (2023 - 2026)

Ginkgo Bioworks Holdings (DNA) EBT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.22%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 12.16%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 86.16%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 41.79%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 95.61%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 38.36%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 64.03%
10 Ginkgo Bioworks Holdings 432.60 Mn 348.06 Mn 18.44 Mn 30.89%

Historic Data

Download Data
DateValue
Jun 30, 2026 30.89%
Mar 31, 2026 28.11%
Dec 31, 2025 24.33%
Sep 30, 2025 50.61%
Jun 30, 2025 55.13%
Mar 31, 2025 48.03%
Dec 31, 2024 59.35%
Sep 30, 2024 17.90%
Jun 30, 2024 -58.11%
Mar 31, 2024 -30.33%
Dec 31, 2023 -65.92%
Sep 30, 2023 -126.35%